Abstract 45P
Background
Although 4 molecular subtypes of endometrial cancer (EC) by The Cancer Genome Atlas (TGGA) have distinctive prognostic features, prognosis within each subtype could vary depending on histological and molecular factors. By merging omics datasets and machine learning analyses, we attempted to identify biomarkers related to the recurrence within each molecular subtype.
Methods
From TCGA multi-omics datasets, 116 EC samples with DNA methylation, RNA-seq, and common variants as well as recurrence data were used for analysis. Differentially expressed genes (DEGs) and differentially methylated regions (DMRs) were retrieved by t-test between the recurrence and non-recurrence groups. DEGs and DMRs were visualized using volcano plots and heat maps. The machine learning approaches, namely decision tree (DT) and random forest (RF) models, were used to find the molecular factors to best discriminate the following 4 groups: copy number-high (CN-H) with recurrence, CN-H without recurrence, copy number-low (CN-L) with recurrence, and CN-L without recurrence. Critical gene expressions or DNA methylation levels in each molecular subtypes were presented as a boxplot.
Results
Three omics datasets were merged with 378,278 CpG sites, 53,409 normalized gene expression levels, 118,555 genomic region variants, and 18,603 gene variants. Through DT and RF, PARD6G-AS1, CSMD1, TESC, and CD44 were selected. Boxplot revealed that hypomethylation of PARD6G-AS1, hypermethylation of CSMD1, and increased TESC expression were significantly associated with increased risk of recurrence in the CN-H group. Also, overexpression of CD44 was significantly associated with recurrence in the CN-L group. After validation of these 4 parameters using TCGA raw data, PARD6G-AS1 and CD44 remained their statistical significance (P=0.006 and 0.020, respectively). Hypomethylation of PARD6G-AS1 in CN-H and CD44 overexpression in CN-L demonstrated significant association with both advanced stage and lymph node metastasis.
Conclusions
Hypomethylation of PARD6G-AS1 in CN-H and CD44 overexpression in CN-L could be predictive markers in endometrial cancer recurrence.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract